Tuesday, August 21, 2018
 
 
Company News: Page (1) of 1 - 02/14/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

(February 14, 2018)

FIT Biotech Oy

Company release February 14, 2018 at 5:30 PM EET

Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the FIT Biotech Oy ("Company") and Suomen Itsenäisyyden Juhlarahasto Sitra ("Sitra") the Company's Board of Directors have resolved on February 14, 2018 to approve Sitra's request relating to the funding programme to convert EUR 73,000 worth of Convertible Capital Notes into the Company's K shares.



Due to the conversion of the Convertible Capital Notes, the Company transfers 19,972,640 new K shares in the Company to Sitra with the conversion price of EUR 0.003655 per share and the share capital of the Company will be increased by EUR 73,000.00. The Board authorization is based on the Extraordinary General Meeting of December 14, 2017.

The K shares will be admitted to trading on First North Finland on or about February 19, 2018.

After this transaction FIT Biotech Oy has listed shares amounting to 260,777,207 K shares.

FIT BIOTECH OY

Board of Directors

For further information:
CEO Erkki Pekkarinen
Tel: +358440270080
E-mail: [email protected]

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • The global connected health device market is expected to reach an estimated $36.1 billion by 2023 and is forecast to grow at a CAGR of 21.1% from 2018 to 2023
  • Global Hemodialysis and Peritoneal Dialysis Market to Witness a CAGR of 5.9% during 2018-2024
  • The Alzheimer's Research and Prevention Foundation (ARPF) Announces Second Brain Longevity® Therapy Training Program in Washington D.C.
  • Image Guided Radiotherapy Market to Experience Unfaltering Growth at 15.8% CAGR to Revolutionize the Healthcare Sector by 2023

    Cancer
  • New ESMO Tumour DNA Scale Helps Match Patients with Cancer to Optimal Targeted Medicines
  • /R E P E A T -- Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution/
  • Singapore's first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
  • Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution
  • ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines